Ultimovacs Q2: INITIUM on track for top-line data in H1 2023E - Redeye

Redeye comments on Ultimovacs’ Q2 2022 report with several potential catalysts on the near- to medium-term horizon. The company reassuringly completed phase II INITIUM patient recruitment in late June, setting the stage for delivering top-line data in H1 2023E.

Länk till analysen i sin helhet: https://www.redeye.se/research/852490/ultimovacs-q2-2022-initium-on-track-for-top-line-data-in-h1-2023e?utm_source=finwire&utm_medium=RSS